{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464380249
| IUPAC_name = (''R'')-''N''-(prop-2-ynyl)-2,3-dihydro-1''H''-inden-1-amine
| image = Rasagiline skeletal.svg
| image2 = Rasagiline-3D-balls-B.png

<!--Clinical data-->
| tradename = Azilect
| Drugs.com = {{drugs.com|monograph|azilect}}
| MedlinePlus = a606017
| pregnancy_category = C
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 36%
| protein_bound = 88 – 94%
| metabolism = [[肝脏|肝脏]]代谢 ([[CYP1A2|CYP1A2]]-mediated)
| elimination_half-life = 3 hours
| excretion = [[尿液|尿液]]和[[粪便|粪便]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 1875-50-9
| ATC_prefix = N04
| ATC_suffix = BD02
| PubChem = 3052776
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01367
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2314553
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 003N66TS6T
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D02562
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 887

<!--Chemical data-->
| C=12 | H=13 | N=1 
| molecular_weight = 171.238 g/mol
| smiles = C#CCN[C@H]2c1ccccc1CC2
| InChI = 1/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1
| InChIKey = RUOKEQAAGRXIBM-GFCCVEGCBG
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RUOKEQAAGRXIBM-GFCCVEGCSA-N
}}

'''雷沙吉兰'''（英文：Rasagiline，AZILECT®），一种[[单胺氧化酶|单胺氧化酶]]的不可逆抑制剂<ref>{{cite journal |author=Oldfield V, Keating GM, Perry CM |title=Rasagiline: a review of its use in the management of Parkinson's disease |journal=Drugs |volume=67 |issue=12 |pages=1725–47 |year=2007 |pmid=17683172 |doi= |url=}}</ref>，作为早期[[帕金森病|帕金森病]]的治疗单药和作为中、晚期帕金森病 [[L-多巴|L-多巴]]（Levodopa） 疗法的附加用药。

== 参考文献 ==
{{Reflist}}

{{抗帕金森病}}
{{抗氧化剂}}